Literature DB >> 15090178

G protein-coupled receptor desensitization as a measure of signaling: modeling of arrestin recruitment to activated CCK-B receptors.

Larry S Barak1, Robert H Oakley, Michael A Shetzline.   

Abstract

Gastrin is one of the principle hormonal mediators of gastric acid secretion, and its cognate receptor (CCK-B) is a member of the superfamily of GPCRs. Patients with hypergastrinemia may present with a variety of symptoms, including gastric ulcers or malignant tumors. Thus, the molecular mechanisms that terminate CCK-B receptor signaling, as well as an ability to measure gastrin bioactivity in a timely manner, have important clinical implications. In order to assess CCK-B receptor regulation, we have constructed a single cell biosensor containing the CCK-B receptor and an arrestin/GFP chimera. The gastrin biosensor responded to both immunologically detectable gastrin-17 and undetectable pentagastrin, and was able to determine the gastrin bioactivity of serum from a patient with clinical hypergastrinemia. We determined that the CCK-B receptor binds arrestin with a pharmacology mirroring CCK-B receptor signaling through inositol phosphate, and that the rate of arrestin dissociation from internalized receptor mirrors receptor recycling to the plasma membrane. Moreover, the CCK-B recycling rate is intermediate between that of Class A GPCRs such as the beta2-adrenergic receptor and Class B GPCRs such as the vasopressin type 2 receptor. Mathematical modeling of these results indicates that a common receptor conformation may underlie both CCK-B signaling and desensitization. In addition to its use in drug screening, this methodology should generalize to other receptors for use in diagnosis and monitoring of bioactive ligands involved in GPCR-based disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15090178     DOI: 10.1089/154065803322163722

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  5 in total

Review 1.  Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.

Authors:  Laurence J Miller; Aditya J Desai
Journal:  Trends Endocrinol Metab       Date:  2016-05-04       Impact factor: 12.015

2.  Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity.

Authors:  Erin E Cawston; Kaleeckal G Harikumar; Laurence J Miller
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-02       Impact factor: 4.249

3.  Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity.

Authors:  Pingwei Zhao; Haleli Sharir; Ankur Kapur; Alan Cowan; Ellen B Geller; Martin W Adler; Herbert H Seltzman; Patricia H Reggio; Susanne Heynen-Genel; Michelle Sauer; Thomas D Y Chung; Yushi Bai; Wei Chen; Marc G Caron; Larry S Barak; Mary E Abood
Journal:  Mol Pharmacol       Date:  2010-07-22       Impact factor: 4.436

4.  Polyunsaturated fatty acids block platelet-activating factor-induced phosphatidylinositol 3 kinase/Akt-mediated apoptosis in intestinal epithelial cells.

Authors:  Jing Lu; Michael S Caplan; Dan Li; Tamas Jilling
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-03-20       Impact factor: 4.052

Review 5.  Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.

Authors:  Erin E Cawston; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.